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Abstract
Objective: To assess the plasma levels and relations of adi-
pocytokines and biochemical bone markers in type 2 diabe-
tes mellitus (T2DM) Saudi males with insulin resistance.
Methods: This case-control study included 80 overweight/
obese males with T2DM on oral anti-diabetic medications
recruited from the diabetic center and 40 healthy lean males
of matched age. Measurements included fasting plasma glu-
cose (FBG), fasting plasma insulin, serum calcium (Ca2 +),
HbA1c, plasma adiponectin and resistin, serum bone-spe-
cific alkaline phosphatase (B-ALP), plasma osteocalcin
(OC), and plasma osteoprotegerin (OPG). Waist and hip
circumferences were measured. Body mass index, waist/
hip ratio (WHR), and insulin resistance (HOMA-IR) were
calculated.
Results: Compared to the control group, diabetic patients
showed significantly both lower adiponectin (p= 0.000)
and Ca2 + (p= 0.000) but significantly higher resistin
(p= 0.000), OC (p= 0.000), B-ALP level (p= 0.000) and
OPG (p= 0.000). After multivariate adjustment in diabetic
patients, resistin predicted OC, (beta = 0.30, p= 0.005),
WC and resistin predicted Ca2+ (beta = 0.34, p= 0.035
and beta = 0.25, p= 0.033), adiponectin and resistin
predicted B-ALP, (beta = 0.35, p= 0.010 and
beta = 0.35, p= 0.004), and FBG, HOMA-IR and age
predicted OPG, (beta = 0.66, p= 0.010, beta = 0.58,
p= 0.024 and beta = 0.27, p= 0.031 respectively). Also,
FBG, WHR and HOMA-IR predicted adiponectin
(beta = 0.79, p= 0.001, beta = 0.60, p= 0.001 and
beta = 0.80, p= 0.001 respectively), while OC and OPG
predicted HbA1c (beta = 0.32, p= 0.007 and
beta = 0.28, p= 0.016 respectively).
Conclusion: Uncontrolled T2DM Saudi males with insulin
resistance have abnormal bone markers with unfavorable
levels of adipocytokines. Strong associations between bone
markers, adipocytokines, insulin resistance and metabolic
control may suggest interaction in multiple direction feed-
back loops exacerbating hyperglycemia.
Keywords: Adipocytokines; Bone markers; Glycemic control;
Insulin resistance; Type 2 diabetes
 2014 Taibah University. Production and hosting by Elsevier
Ltd. All rights reserved.
Introduction
Adipose tissue secretes a large number of physiologically active
peptides ‘‘adipocytokines”.1 Adiponectin is an anti-inflamma-
tory adipocytokine with a 30 kDa complement-related pro-
tein.2 It is induced during adipocyte differentiation and
secreted in response to stimulation by insulin. Adiponectin
and its receptors have been found to be produced by human
bone-forming cells, suggesting that adiponectin may be a hor-
mone linking bone and fat metabolism.3 Resistin, a 12.5-kDa
protein is a pro-inflammatory cytokine that is produced in
the stromovascular fraction of the adipose tissue and in the
peripheral blood monocytes.4 Given the incomplete homology
between human and mouse resistin, human resistin may have a
different physiologic role than mouse resistin.5,6 Elevated plas-
ma concentrations of resistin have been documented in adults
with obesity, insulin resistance, and type 2 diabetes mellitus
(T2DM), while plasma concentrations of adiponectin are re-
duced in adults with these conditions.7 While insulin resistance
and the frequently associated obesity are the major determi-
nants of T2DM, still less information is available on how obes-
ity and insulin resistance affect the plasma adipokine profile in
diabetic patients. Recent research3,8 has revealed many func-
tions of adipocytokines including bone formation. Therefore,
adipocytokines might be involved in the overlooked bone dis-
ease complication of T2DM. There is good evidence that pa-
tients with T2DM have increased bone fragility and fracture
risks up to 1.5-fold irrespective of their bone mineral density
(BMD).9 Many bone markers are found to be abnormal in
uncontrolled T2DM including low osteocalcin (OC), high
bone alkaline phosphatase (B-ALP) and osteoprotegerin
(OPG) levels with some improvements after glycemic con-
trol.10,11 OC and B-ALP serum concentrations generally reflect
bone formation by mature and immature osteoblasts respec-
tively.12 While, OPG is an antiresoptive bone marker that is
a strong inducer of osteoclast differentiation, its exact role in
bone regulation is not yet established.13,14
Despite the above findings, the relationship of adipocyto-
kines with bone markers, insulin resistance, and metabolic
control has been the subject of few and controversial reports
depending on the study population.15 Therefore, the objectives
of this case control study were to assess the plasma levels and
relations of adipocytokines and biochemical bone markers in
T2DM obese/overweight Saudi males in comparison with
healthy lean adults and to study their possible relationship
with metabolic control and insulin resistance parameters in
the same population. In this study only male subjects were in-
cluded to avoid any possible influences of gender on the adipo-
cytokines and bone markers.
Materials and Methods
Study population: this was a preliminary study where little was
known about the association between the adipocytokines and
metabolic control, insulin resistance and bone markers among
Saudis. The sample size of 120 depended on the number of pa-
tients and controls who could be recruited according to the
inclusion and exclusion criteria in the time frame between
December 2011 to November 2012.
Eighty Saudi males between the ages of 35–55 years with
T2DM, under oral anti-diabetic medications were sequentially
recruited from the Diabetes Center in AL-Madinah A-Mun-
awwarah. The patients were selected randomly from the list
of the attendants at this center, who were asked to participate.
The inclusion criteria were only applied to those patients who
agreed to participate. All the patients included in the study
were overweight or obese with or without Acanthosis Nigri-
cans. They were also under primary prevention of coronary ar-
tery disease including Aspirin and HMG-COA reductase
inhibitors (statins). Meanwhile patients on oral anti-diabetic
thiazolidinedione, insulin therapy or had cardiac or renal
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complications, urinary tract infection or liver function abnor-
malities were excluded. Exclusion criteria also included pa-
tients with cushing syndrome, acromegaly, and stress states
(trauma, surgery, diabetes ketoacidosis, severe infection) or
on medications associated with insulin resistance syndrome
(glucocorticoids, cyclosporine, niacin, and protease inhibitors)
or bone remodeling (glucocorticoids, disphosphatase, calcium
or vitamin D, vitamin K deficiency). The use of antihyperten-
sive medication was allowed.
Forty healthy Saudi male volunteers of similar ages were se-
lected randomly from attendants of the OPD at Taibah Uni-
versity in AL-Madinah AL-Munawwarah. All volunteers
were lean with BMI <25 kg/m2. An informed consent was ta-
ken from patients and control subjects to participate in this
study. The study adhered to the tenets of the Declaration of
Helsinki, and it was approved by the Deanship of Scientific
Research, Taibah University.
Clinical data
All patients and controls were submitted to full history taking,
thorough clinical examination and anthropometric measure-
ments. The latter had included weight, height, waist circumfer-
ence (WC) (the minimum distance between the iliac crest and
the lateral costal margin), and hip circumference (at the max-
imum area of the buttocks). Calculations were performed for
waist to hip ratio (WHR) and body mass index (BMI) (weight
in kilograms/height (square meters)). However, the prevalence
of metabolic syndrome could not be performed in this study as
all participants were under anti-hyperlipidemic treatment.
Laboratory analyses
All participants were studied after an overnight fast and the
diabetic patients did not take their usual medication before
blood sampling. Twelve ml of venous blood were withdrawn
and received in 3 test tubes. The first was left for 10 min (to al-
low clot formation) then centrifuged at 3000g for 10 min. The
serum was separated. Part of the fresh serum was used for
spectrophotometric measurements of lipid profile using kits
for triglycerides, cholesterol, high-density lipoprotein-choles-
terol (HDL-c), and low-density lipoprotein cholesterol
(LDL-c) provided by Biosystems S.A. Barcelona-Spain. The
remaining part of the serum was stored at 80 C until bio-
chemical analysis of serum bone-specific alkaline phosphatase
(BAP) isoenzyme by BAP EIA Kit, Microvue Bone Health,
USA. The entirety of the blood sample in the second tube
was used fresh for measurement of hemoglobin A1C (HbA1c)
by NycoCard HbA1c kit, NycoCard, Oslo, Norway using
NycoCard reader II instrument- Oslo, Norway. The third tube
was heparinized and its blood content was centrifuged at 3000g
for 10 min and the plasma was separated. Part of the fresh
plasma was used for spectrophotometric measurement of fast-
ing plasma glucose using glucose kit provided by Biosystems S.
A. Barcelona-Spain. The remaining part of the plasma was
stored at 80 C until biochemical analysis of the remaining
parameters. The plasma level of the adiponectin was measured
by Assay Max Human Adiponectin ELISA kit, Assaypro,
USA. While the plasma level of resistance was measured by
Assay Max Human Resistance ELISA kit, Assaypro, USA.
Measurement of serum calcium (Ca2+) level was measured
colorimetrically by Ca2+ kit, Randox laboratories LTD,
UK. Plasma osteocalcin (OC) and osteoprotegerin (OPG) were
measured by Human Osteocalcin Instant ELISA and Human
Osteoprotegerin Instant ELISA kits respectively, eBioscience,
North America. Measurement of fasting plasma insulin level
was performed by AccuBind ELISA Microwells kit for insulin,
Monobind Inc. USA. Spectrophotometric assays were done
using Spectro UV–Vis Double Beam PC 8 scanning autogell
UVD-3200, Labmed, Inc.USA, while EIA and ELIZA mea-
surements were done using Anthos microplate absorbance
reader 2010, Anthos Labtec Instruments, Austria. Conditions
of kits storage and handling were followed according to the
instructions provided by the manufacturers.
All samples and standards were measured in duplicates for
each assay test and the mean value of the duplicate readings
for each standard and sample was calculated. A standard curve
for each assay test has been plotted and the unknown sample
concentration was determined from the standard curve and
the value was multiplied by the dilution factor if there was
dilution of the sample. Internal quality control to check the
precision of lab work and external quality assessment to check
the analytical part of the test have been strictly performed.
Proficiency surveillance has been done to ensure adequate con-
trol of the pre and post analytical stages of each test. It implies
critical supervision of all the aspects of laboratory tests such as
patient identification, sample collection and handling, labeling,
delivering, and storage. It also included reading and reporting
of results, establishment of normal reference values as well as
maintenance and control of apparatus and instruments. Stan-
dardization of test results has also been done.
Insulin resistance was assessed using the homeostasis model
assessment (HOMA-IR) with the following formula:16
HOMA-IR ¼ fasting plasma glucose ðmmol=lÞ
 fasting plasma insulin ðlU=mlÞ=22:5
Statistical analyses
All the study data were analyzed using the SPSS 18.0 software
for Windows (PASW statistics 17). Continuous variables were
summarized as median as most variables were not normally
distributed. Mann–Whitney test was used to compare 2 inde-
pendent not normally distributed variables. Multiple linear
regressions were used to identify relations between different
parameters in T2DM. For all statistics, a two-sided p-value
<0.05 was considered statistically significant.
Results
The study revealed that the control and T2DM group were
age-matched (p= 0.87) (Table 1). The median T2DM dura-
tion was 5.25 years. Twenty patients (25%) were hypertensive
and 16 patients (20%) were having diabetic neuropathy. Only
10 out of 80 diabetic patients (12.5%) were controlled with
HbA1c 67%.
Compared to the control group, the T2DM group showed
significant increase in the median BMI (30.93 vs. 22.54 kg/cm2,
p= 0.000), WC (100.5 cm vs. 77.5 cm, p= 0.000), and WHR
(0.97 vs. 0.85, p= 0.000). Also diabetic group had significantly
higher median levels of HbA1c (8.15 vs. 5.60%, p= 0.000),
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fasting plasma glucose (10.03 vs. 4.70 mmol/l, p= 0.000), fast-
ing plasma insulin (40.05 vs. 9.10 lU/ml, p= 0.000), and
HOMA-IR (17.49 vs. 1.9, p= 0.000).
For lipid profile, there was significant increase in the
median plasma TG and decrease in plasma HDL-c in the
T2DM group compared to the control group (1.60 vs
0.64 mmol/l, p= 0.000 and 0.95 vs 1.14 mmol/l, p= 0.035
respectively), whereas plasma total cholesterol and plasma
LDL-c showed no significant changes.
Diabetic patients showed a significant decrease in the med-
ian levels of plasma adiponectin (7.16 vs. 12.06 ug/ml,
p= 0.000) and a significant increase in plasma resistin (5.73
vs. 3.44 ng/ml, p= 0.000) compared to the control group (Ta-
ble 2). They also had a significant decrease in the median levels
of serum calcium (2.03 vs. 2.25 mmol/l, p= 0.000) and plasma
OC levels (6.4 vs. 21 ng/ml, p= 0.000) with a significant in-
crease in the median levels of serum B-ALP (56.3 vs. 42.2 U/
l, p= 0.000) and plasma OPG levels (67.9 vs. 46.2 pg/ml,
p= 0.000) (Table 2).
Using multiple linear regression in T2DM patients, insulin
resistance parameters (WC, WHR, BMI, and HOMA-IR),
diabetes control parameters (FBG and HbA1C), and plasma
adipocytokines (resistin and adiponectin) significantly
predicted bone metabolic markers (plasma OC (F= 4.2,
p< 0.001), serum Ca2+ (F= 2.41, p= 0.030), serum
B-ALP (F= 2.25, p= 0.034) and plasma OPG (F= 2.32,
p= 0.025).
After a multivariate adjustment, plasma resistin remained
significant in predicting plasma OC, (beta = 0.30,
p= 0.005), WC and plasma resistin remained significant in
predicting serum Ca2+ (beta = 0.34, p= 0.035 and
beta = 0.25, p= 0.033 respectively), plasma adiponectin
and resistin remained significant in predicting serum B-ALP,
(beta = 0.35, p= 0.010 and beta = 0.35, p= 0.004), and
the FBG, HOMA-IR and age remained significant in predict-
ing the plasma OPG, (beta = 0.66, p= 0.010, beta = 0.58,
p= 0.024 and beta = 0.27, p= 0.031 respectively) (Table 3).
Also on the multiple linear regression analysis, insulin resis-
tance and metabolic control parameters predicted plasma
adiponectin (F= 4.80, p= 0.001) but not plasma resistin.
Table 1: Anthropometric, clinical, and biochemical data of diabetes and lean control groups.
Parameter Control group (Median) Diabetes group (Median) P
Age (years) 41.50 41.50 0.87
BMI (kg/cm2) 22.54 30.93 0.000
WC (cm) 77.5 100.5 0.000
WHR 0.85 0.97 0.000
FBG (mmol/l) 4.70 10.03 0.000
HbA1C (%) 5.60 8.15 0.000
Plasma insulin (lU/ml) 9.10 40.05 0.000
Plasma TC (mmol/l) 4.78 4.4 0.092
HOMA-IR 1.9 17.49 0.000
Plasma TG (mmol/l) 0.64 1.60 0.000
Plasma LDL-c (mmol/l) 2.62 1.90 0.057
Plasma HDL-c (mmol/l) 1.14 0.95 0.035
BMI: body mass index, WC: waist circumference, WHR: waist-to-hip ratio, FBG: fasting blood glucose, HbA1c: hemoglobin A1c, TC: total
cholesterol, HOMA-IR: homeostasis model assessment-insulin resistance, TG: triglycerides, LDL-c: low-density lipoprotein cholesterol,
HDL-c: high-density lipoprotein cholesterol.
Table 2: Adipocytokines and bone markers in diabetes and lean control groups.
Marker Control group (Median) Diabetes group (Median) P
Adipocytokines Plasma adiponectin (lg/ml) 12.06 7.16 0.000
Plasma resistin (ng/ml) 3.44 5.73 0.000
Bone formation markers Serum calcium (mmol/l) 2.25 2.03 0.000
Plasma OC (ng/ml) 21 6.4 0.000
Serum B-ALP (U/l) 42.2 56.3 0.000
Bone antiresorption marker Plasma OPG (pg/ml) 46.2 67.9 0.000
OC: osteocalcin, B-ALP: bone-specific alkaline phosphatase, OPG: osteoprotegerin.
Table 3: Multiple linear regression analysis of glycemic control
parameters, insulin resistance, adipocytokines, and bone markers.
Parameter Predictors Beta P
OC Resistin 0.30 0.005
B-ALP Resistin 0.35 0.004
Adiponectin 0.35 0.010
Serum Ca2+ WHR 0.34 0.035
Resistin 0.25 0.033
OPG FBG 0.66 0.010
HOMA-IR 0.58 0.024
Age 0.27 0.031
Adiponectin FBG 0.79 0.001
WHR 0.60 0.001
HOMA-IR 0.80 0.001
HbA1C OC 0.32 0.007
OPG 0.28 0.016
OC:osteocalcin, B-ALP: bone-specific alkaline phosphatase, OPG:
osteoprotegerin, HbA1c: hemoglobin A1c, WHR: waist-to-hip
ratio, FBG: fasting blood glucose, HOMA-IR: homeostasis model
assessment-insulin resistance.
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After adjustment, the FBG, WHR and HOMA-IR remained
significant in predicting plasma adiponectin (beta = 0.79,
p= 0.001, beta = 0.60, p= 0.001 and beta = 0.80,
p= 0.001 respectively), while plasma OC and plasma OPG
predicted HbA1c (beta = 0.32, p= 0.007 and beta = 0.28,
p= 0.016 respectively). Plasma adipocytokines and plasma/
serum bone markers predicted HbA1c (F= 2.956,
p= 0.013). After adjustment, the plasma OC and plasma
OPG remained significant in predicting HbA1c (beta = 0.32,
p= 0.007 and beta = 0.28, p= 0.016 respectively) (Table 3).
Discussion
In this study, obese/overweight T2D Saudi males were charac-
terized by clinical evidence of insulin resistance and poor met-
abolic control.17–21 They had disturbed plasma/serum bone
markers with low serum calcium and plasma OC coupled with
high serum B-ALP and plasma OPG. Unfavorable combina-
tion of the 2 adipocytokines (high plasma resistin and low plas-
ma adiponectin) was also detected. Complex strong
associations were detected between adipocytokines, bone
markers, as well as markers of metabolic control.
The discrepancy in the bone formation markers (low plas-
ma OC and the low serum Ca2+ coupled with high serum B-
ALP levels) in this study, as well as in others,22–25 could be ex-
plained by hyperglycemia itself. Several studies indicated that
hyperglycemia and advanced glycation end products stimulate
the apoptosis of osteoblastic cells22–28 and restrain their differ-
entiation resulting in suppression of serum osteocalcin (OC)
and cellular calcium uptake.27,28 Also, chronic hyperglycemia
increases the activity and expression of alkaline phosphatase.28
Impaired osteoblastic maturation results in increased bone fra-
gility and fracture rates in patients with T2DM irrespective of
their bone mineral density (BMD).9 This state of low turnover
with low plasma OC could also be explained by the low plasma
adiponectin level seen in this study, as well as in others.26,27
Adiponectin through its bone receptors enhances the prolifer-
ation, differentiation, and mineralization of osteoblastic
cells.3,28 Adiponectin has been shown to enhance the receptor
activator of nuclear factor-jB ligand (RANKL) expression
and inhibits osteoprotegerin (OPG) expression.29 Therefore,
low plasma adiponectin in T2DM could explain the high plas-
ma level of the anti-resorption marker OPG in this study in
concordance with other studies.30,31 Another explanation of
the high plasma OPG is insulin resistance as HOMA-IR was
an independent predictor of plasma OPG similar to results
of Gannage´-Yared et al. who studied obese subjects.31
Results of the present study showed that FBG, HbA1C, and
WC were negative predictors of adiponectin. In accordance
with these results, two studies, performed on Saudis, linked
visceral adiposity32 and glycaemic disturbances32,33 to adipo-
nectin. Moreover, these results are consistent with what is
known as ‘‘adipoinsular axis’’ between adipose tissue and pan-
creatic islet cells.34 Therefore hypoadiponectinemia in T2DM
could represent the link between metabolic control, insulin
resistance and bone.35
High plasma resistin level in T2DM participants was re-
ported by many studies and was found in parallel with bone
changes.22,24,29 Resistin predicts OC and calcium negatively
and B-ALP positively. In our cohort, high plasma resistin
was not related to insulin resistance or metabolic control in
contrast to another study done on Saudis,36 as well as in other
nationalities.37,38 In contrast to adiponectin, resistin is ex-
pressed mainly in circulating blood monocytes rather than adi-
pose tissue39 and this predominantly paracrine role of resistin
could explain the controversy of results between different
studies.
Present results showed that plasma OC and OPG predicted
HbA1C in the direction of hyperglycemia. Other researchers
found that plasma OC is a positive regulator of insulin secre-
tion and insulin sensitivity and can be involved in glycemic
control.39–41 Multiple relations detected in this study between
adipose tissue, pancreatic islets and bone cells could reflect
complex feedback loops probably leading to exacerbation of
hyperglycemia.
To the best of our knowledge, the current study is the first
study to assess adipocytokines, bone markers and glucose
homeostasis profile in T2D Saudi adults. Our sample com-
prised of adult Saudi males based on the available evidence
of gender influence on levels of adipocytokines in Saudis42
and in others43,44 as well as on levels of bone markers.45
The main limitation of this study is its preliminary case-
control design which cannot prove causation or reverse causa-
tion speculated. Also generalization of the results of the study
is limited due to the homogeneity of the study population.
Moreover, interpreting bone metabolic markers in diabetic pa-
tients represents an additional limitation as it could be flawed
by hyperglycemia, insulin deficiency and advanced glycated
end products.46 In addition, single measurements of the adio-
pokines and bone markers may not reflect their long-term le-
vel. Finally, although data analysis was adjusted for known
confounders, imperfectly measured or unmeasured confound-
ers could not be excluded including the use of antihypertensive
agents.
Conclusion
Overweight/obese T2D Saudi males with insulin resistance
have decreased serum Ca2+ and OC with increased B-ALP
and OPG bone markers. They had an unfavorable combina-
tion of the 2 adipocytokines (high resistin and low adiponec-
tin). Hypoadiponectemia could represent the link between
metabolic control and insulin resistance. The data support a
regulatory role for resistin in the modulation of bone that
needs further explanation. Strong associations between adipo-
cytokines, insulin resistance, metabolic control and bone
markers may suggest interaction in multiple direction feedback
loops leading to exacerbation of hyperglycemia.
It is recommended to further study the endocrine functions
of adipose tissue and bone especially in uncontrolled T2D pa-
tients in order to elucidate their possible role in glucose
homeostasis.
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